Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Income Statement
Cash Flow Statement
Balance Sheet
Earnings Release
EX-99.1 2 tmci-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Treace Medical Concepts Reports Second Quarter 2026 Financial Results PONTE VEDRA, Fla.
EX-99.1 2 tmci-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Treace Medical Concepts Reports Second Quarter 2026 Financial Results PONTE VEDRA, Fla. – August 7, 2026 – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related deformities, today reported financial results for the second quarter ended June 30, 2026. Recent Highlights • Generated revenue of $45.4 million in the second quarter 2026 compared to $47.4 million in the same period in 2025. • Reported second quarter 2026 net loss of $(15.9) million and adjusted EBITDA of $(3.5) million in the second quarter 2026. • Reduced year-to-date cash usage by 57% or $3.6 million when compared to the same period in 2025. Cash, cash equivalents, and marketable securities totaled $45.6 million as of June 30, 2026. • Initiated l...
Source
Exhibit EX-99.1
0001630627-26-000017
Filed August 7, 2026 at 11:10 AM UTC. The figures above are from the audited statements, not from this release.